08:38 AM EDT, 03/11/2024 (MT Newswires) -- Nurix Therapeutics ( NRIX ) said Monday that the US Food and Drug Administration has lifted the partial clinical hold on its phase 1a/1b study of NX-2127 in adults with relapsed or refractory B-cell malignancies.

The company said the hold was placed after Nurix told the FDA that it was changing its manufacturing process.

Nurix said it plans to resume enrollment in the trial, which will use the new manufacturing process, and prioritize patients with aggressive forms of non-Hodgkin's lymphoma. Patients participating in the study using the prior process may continue their treatment, the company added.

Price: 15.01, Change: +0.16, Percent Change: +1.08